Study Published in Journal of Dental Research Demonstrates Value of Genetics in Preventing Periodontal Disease

  Study Published in Journal of Dental Research Demonstrates Value of Genetics
  in Preventing Periodontal Disease

    Genetics-based Risk Assessment Brings Personalized Preventive Care to
                                  Dentistry

Business Wire

WALTHAM, Mass. -- June 10, 2013

Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the online
publication of the research study “Patient Stratification for Preventive
Dental Care” in Journal of Dental Research. The study provides new insights
into the prevention of periodontitis (gum disease) and the opportunity for
significant advancement in the delivery of personalized, preventive dental
care. Periodontitis affects 47 percent of the adult population.

The study explored the influence of three key risk factors for periodontal
disease—smoking, diabetes and genetics—on tooth loss given varied frequencies
of preventive dental visits that included cleanings. By examining claims data
from 5,117 patients without periodontitis throughout a 16 year period and
conducting genetic testing, researchers determined that patients with genetic
variations of the IL-1 genotype, or one or more other risk factors examined,
were at significantly increased risk for tooth loss and therefore require more
preventive dental care. The IL-1 genetic variation was the single most
prevalent risk factor—nearly one in three Americans carry this genetic
variation. This study demonstrates the important opportunity to provide more
effective preventive oral care through the use of risk-based patient
assessment that includes genetic testing.

Research was conducted under the direction of Dr. William Giannobile, Najjar
endowed Professor of Dentistry and Biomedical Engineering, and Chair of the
Department of Periodontics and Oral Medicine at the University of Michigan.

Periodontitis is a bacterially induced chronic inflammatory disease that
destroys the bone and gum tissues that support the teeth. It is one of the
most common chronic diseases of the body. It causes bleeding and swelling of
the gums, loose teeth, bad breath and can ultimately lead to tooth loss.
Severe periodontitis has been associated with increased risk for multiple
other diseases, including cardiovascular diseases, diabetes and rheumatoid
arthritis. One in four Americans over age of 65 have lost all their teeth.

“Dentistry has long been a leader in the delivery of preventive healthcare to
patients. The findings of this study provide dental clinicians with the
opportunity to offer personalized, preventive care that is based on new
insights into the importance of genetic risk factors,” said Dr. Kenneth
Kornman, Chief Executive Officer of Interleukin Genetics, which developed the
genetics test used in the study.

“Personalized medicine is an important frontier in healthcare driven by the
clinical application of genetic and molecular information. Genetic-based risk
assessment has long promised to improve prevention and treatment of chronic
diseases,” said Sir Gordon Duff, Professor Emeritus of Molecular Medicine the
University of Sheffield and co-author of the paper. “The findings of this
study represent perhaps the first broad scale application of genetics to help
prevent a disease that is very prevalent, costly and preventable.”

Periodontitis initiation and progression is driven by two factors: bacterial
plaque that initiates the disease and the body’s inflammatory response to
bacteria which, when overly aggressive, causes breakdown of the bone and
tissue that support the teeth. This inflammatory response varies greatly
within the population and is significantly impacted by individual genetic
make-up. Genetic testing can identify patients who have an increased
inflammatory response to oral bacteria which significantly increases risk of
periodontitis and tooth loss. Smoking and diabetes also contribute
significantly to the risk of periodontal disease.

“Ultimately, patients should be evaluated by their dentist regularly and
receive needed preventive care before any symptoms of periodontal disease
appear. This disease can result in disfiguring bone loss around teeth and has
been implicated as a risk factor for multiple systemic conditions that benefit
from early stage prevention,” said periodontist Donald S. Clem, III, D.D.S.,
Diplomate, American Board of Periodontology, Past President American Academy
of Periodontology. “Historically, we have lacked the prognostic tools to
effectively identify patients at greatest risk for periodontitis. This study
underscores the need to adopt a genetic, risk-based approach and gives
patients a compelling new reason to visit the dentist for a comprehensive
periodontal evaluation. As we see with other chronic diseases, identifying and
understanding genetic predisposition to disease is a critical component of
long term prevention."

For additional details, the study “Patient Stratification for Preventive
Dental Care” Giannobile et al. 2013 from Journal of Dental Research, can be
accessed online.

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of
genetic tests under the Inherent Health^® and PST^® brands.The products
empower individuals to prevent certain chronic conditions and manage their
existing health and wellness through genetic-based insights with actionable
guidance. Interleukin Genetics leverages its research, intellectual property
and genetic panel development expertise in metabolism and inflammation to
facilitate the emerging personalized healthcare market. The Company markets
its tests through partnerships with health and wellness companies, healthcare
professionals and other distribution channels. Interleukin Genetics’ flagship
products include its proprietary genetic risk panel for periodontal disease
and tooth loss susceptibility sold through dentists and the Inherent Health
Weight Management Genetic Test that identifies the most effective diet and
exercise program for an individual based on genetics. Interleukin Genetics is
headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA
testing laboratory certified under the Clinical Laboratory Improvement
Amendments (CLIA). For more information, please visit www.ilgenetics.com.

Certain statements contained herein are “forward-looking” statements,
including statements relating to the opportunity to provide more effective
preventive oral care by the use of risk-based patient assessment that includes
genetic testing.Because such statements include risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to, those risks and uncertainties described in
the Interleukin Genetics’ annual report on Form 10-K for the year ended
December 31, 2012 and other filings with the Securities and Exchange
Commission. Interleukin Genetics disclaims any obligation or intention to
update these forward-looking statements.

Contact:

Media Contacts:
Schwartz MSL
Lauren Arnold/Stacey Holifield, 781-684-0770
interleukingenetics@schwartzmsl.com
or
Investor Contact:
Interleukin Genetics, Inc.
Eliot Lurier, 781-398-0700 ext.1204
Chief Financial Officer
elurier@ilgenetics.com
 
Press spacebar to pause and continue. Press esc to stop.